Project Grant R21NS147536
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $436K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (Massachusetts General Hospital) $648,672 on June 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate circadian regulation of reperfusion efficacy in acute ischemic stroke. The research employs a translational approach combining clinical neuroimaging, biomarkers, mouse models of stroke, CT-PET imaging of tissue...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $439,150 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate exercise preconditioning and compensatory oligodendrogenesis in subcortical ischemic vascular dementia. The research examines white matter damage in vascular contributions to cognitive impairment and dementia, with focus on oligodendrocyte precursor...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $616,126 on August 26, 2026, to conduct in vivo genome editing research for cerebrovascular disorders under NINDS Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award funds research defining how and when gene editing can restore cerebrovascular and white matter integrity in an ACTA2 R179H...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $322,382 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating cell-specific interleukin-1 receptor 1 (IL-1R1) signaling in focal and diffuse traumatic brain injury models. The research uses genetically engineered mice with precise...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1.854 million on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research into compartmentalized reactive oxygen species (ROS) sensing in the brain, specifically investigating how neurons balance mitochondrial energy production with ROS control....
- The National Institutes of Health Office of the Director awarded The General Hospital Corporation (Massachusetts General Hospital) $783,750 under the Trans-NIH Research Support program (CFDA 93.310) on September 1, 2026, to conduct therapeutic discovery in neurodegeneration using bioengineered organoids and artificial intelligence-driven genomics approaches. The award funds development of multiplexed differentiation strategies to generate midbrain organoids that integrate all major brain cell...
- The National Institute of Neurological Disorders and Stroke awarded $574,660 to Icahn School of Medicine at Mount Sinai on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate neutrophil extracellular trap mitigation in ischemic stroke outcomes. The research addresses vascular contributions to cognitive impairment and dementia following acute ischemic stroke by examining how neutrophils form extracellular...
- The National Institute of Neurological Disorders and Stroke awarded Brigham & Women's Hospital $745,570 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the genome-wide association study (GWAS) based neurovascular etiology of migraine and its associated risk of ischemic stroke. The research addresses the gap between recent genetic discoveries identifying 123 migraine susceptibility loci and...
- Dr. Mark Etherton of Massachusetts General Hospital will receive $338,509.06 from the National Institute of Neurological Disorders and Stroke to study microvascular dysfunction in cerebral small vessel disease and stroke outcomes over four years from July 2021 through April 2026. This Project Grant will support research to elucidate the relationship between white matter microvascular function, ischemic tissue outcomes, and chronic microvascular dysfunction's contribution to structural injury and...
- The National Institute of Neurological Disorders and Stroke awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $616,031 on May 5, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate arterial endothelial pannexin 1 channels in ischemic stroke-induced vascular dementia, with specific focus on age and sex differences. The research examines the role of cerebral endothelial pannexin 1 (PANX1)...